What is NDC 84103-007?

84103-007 is the product NDC for Zevaskyn (prademagene zamikeracel), Prademagene zamikeracel 40 cm2/1 cellular sheet, listed with the FDA by Abeona Therapeutics Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.

What drug is associated with this NDC?

Zevaskyn (Prademagene zamikeracel).

Abeona Therapeutics Inc., NDC labeler code 84103. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Zevaskyn?

None: this is the only finished product listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Zevaskyn NDC 84103-007 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)84103-007Labeler and product segments. Claims need a package NDC.

Product NDC at billing width84103-0007Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
84103-007-01	84103000701	4 CELLULAR SHEET in 1 BAG (84103-007-01)Marketed from Jun 15, 2025

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Zevaskyn
Generic name (nonproprietary): prademagene zamikeracel
Active ingredients: Prademagene zamikeracel — 40 cm2/1
Dosage form: Cellular sheet
Route: Topical
Labeler: Abeona Therapeutics Inc.NDC labeler code 84103
Product type: Prescription drug
Marketing category: BLA — Biologics License ApplicationApplication BLA 125807
Marketing start: Jun 15, 2025
Listing expires: Dec 31, 2027
Identifiers: Product ID 84103-007_08bab4ea-47c5-4f67-8c6e-fdbfd6330655SPL ID 08bab4ea-47c5-4f67-8c6e-fdbfd6330655SPL set ID f8782480-8782-4748-9764-b9ed60979d47RxCUI 2713347, 2713352UNII 4UU2O40RHU

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Topical products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N484103000701 followed by a unit qualifier and the quantity

Package 84103-0007-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Mar 19, 2026.

Indications (excerpt from the label)

ZEVASKYN is indicated for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). ZEVASKYN is an autologous cell sheet-based gene therapy indicated for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). ( 1 )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 84103-007

What is NDC 84103-007?: 84103-007 is the product NDC for Zevaskyn (prademagene zamikeracel), Prademagene zamikeracel 40 cm2/1 cellular sheet, listed with the FDA by Abeona Therapeutics Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Zevaskyn (Prademagene zamikeracel).
What is the active ingredient?: Prademagene zamikeracel.
Who is the labeler?: Abeona Therapeutics Inc., NDC labeler code 84103. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Zevaskyn?: None: this is the only finished product listed under this name.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Zevaskyn (Prademagene zamikeracel) NDC 84103-007